<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848571</url>
  </required_header>
  <id_info>
    <org_study_id>sippr</org_study_id>
    <nct_id>NCT04848571</nct_id>
  </id_info>
  <brief_title>Effects of Chinese Medicine on Early Pregnant Women</brief_title>
  <official_title>Effects of Chinese Medicine on Early Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Meiji Health Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Institute of Palnned parenthood research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Meiji Health Science and Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      From April 2021 to December 2021, 50 pregnant women who received intro fertilization (IVF)&#xD;
      will be recuited. Among them, 25 of them would like to take Chinese fetal protection medicine&#xD;
      from the fourth week of pregnancy (experimental group), while the remaining 25 will not&#xD;
      (control group). Blood and feces will be collected in the early morning of the 6th week after&#xD;
      successful transplantation to detect 16S DNA in feces, plasma metabonomics, and whole blood&#xD;
      transcriptomics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators planned to performed a randomized trial to determine the effects of the Chinese&#xD;
      medicine used in pregnant women for fetal protection, including mainly radix polygoni&#xD;
      multiflori, Rehmannia glutinosa. Two groups will be recruited, 25 pregnant women by IVF&#xD;
      without medicine and 25 with the Chinese medicine. In the fourth week, blood, plasma and&#xD;
      fetal are sampling for metabolic and intestinal analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 21, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>16s DNA analysis in feces</measure>
    <time_frame>the fourth week in early pregnancy</time_frame>
    <description>intestinal flora analysis in patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma metabonomics analysis by GC/LC mass</measure>
    <time_frame>the fourth week in early pregnancy</time_frame>
    <description>plasma metabolic analysis in patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>whole blood transcriptomics analysis by RNA sequencing</measure>
    <time_frame>the fourth week in early pregnancy</time_frame>
    <description>blood transcriptomic analysis in patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pregnant Women</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pregnant women who received IVF and not taken Chinesene fetal protection medicine until sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medicine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant women who received IVF and have taken Chinesene fetal protection medicine from the fourth week during early pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Fetal Protection Pill</intervention_name>
    <description>A Chinese medicine used in pregnant women for fetal protection, including mainly radix polygoni multiflori, Rehmannia glutinosa.</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>medicine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  recieved IVF&#xD;
&#xD;
          -  childbirth without miscarriage&#xD;
&#xD;
          -  taking vitamins during pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  miscarrige&#xD;
&#xD;
          -  missed sampling in the fourth week of pregnancy&#xD;
&#xD;
          -  not appropriate judged by the doctor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

